Vivus (VVUS) is raising the bar on erectile dysfunction drugs, potentially becoming the latest formidable competitor to Viagra and Cialis in the $3.8 billion market. Investors in the California-based

It’s a small shot in the arm, but it could mean big money for pharmaceutical companies around the world. With flu season upon us and swine flu threatening to reach pandemic proportions, Big Pha

Editor's note: This article was written by Michelle Leder, who combs through SEC filings for nuggets of interesting details for her blog, Footnoted.org.Now that the merger between Pfizer (PFE) and Wy

Some say the Eighties officially ended last week, Wall Street instead waxing nostalgic for the millennial madness of 1999. But with insider trading (see also Should Insider Trading Be Legalized?)&nbs

What a difference a day makes. I’m not sure what happened, but the back pain I’ve been complaining about the last couple of days just up and disappeared. I feel like I grew an inch overni

The recession is taking a bite out of brand-name products. Only 48% of a brand’s highly loyal customers in 2007 stuck with the label in 2008, a study conducted by Catalina Marketing’s Poi

Big Pharma Gets Bigger After spending $6.5 billion for ImClone last November, Eli Lilly (LLY) CEO John Lechleiter said he’s still hungry for more. According to the Wall Street Journal, Mr.

Roche’s $46.8 billion takeover of Genentech (DNA) will give the Swiss company control of Avastin and Herceptin, promising cancer treatments. The bet: Results on Avastin’s clinical tr

Equity markets had their biggest rally this year after Federal Reserve Chairman Ben Bernanke outlined steps to fix the banking industry in a morning address. His remarks, delivered to the Counci

What a day it was for the market. Turnaround Tuesday definitely lived up to the hype.Citigroup (C) came out and said they had 2 profitable quarters through the first 3 months of this year; all the ba